BioLineRx (BLRX) Tops Q2 EPS by 69c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
BioLineRx Reports Second Quarter 2020 Financial Results and Provides Corporate Update
August 6, 2020 7:00 AM EDTTEL AVIV, Israel, Aug. 6, 2020 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today reports its financial results for the quarter ended June 30, 2020 and provides a corporate update.
Highlights and achievements during the second quarter 2020 and subsequent period:
Continued to advance clinical programs, with three key data readouts in pancreatic cancer, stem cell mobilization and AML expected between now and year-end; Announced publication in the peer-reviewed journal Nature Medicine of previously disclosed... More